TWI348375B - Peptides and compounds that bind to a receptor - Google Patents

Peptides and compounds that bind to a receptor

Info

Publication number
TWI348375B
TWI348375B TW093125674A TW93125674A TWI348375B TW I348375 B TWI348375 B TW I348375B TW 093125674 A TW093125674 A TW 093125674A TW 93125674 A TW93125674 A TW 93125674A TW I348375 B TWI348375 B TW I348375B
Authority
TW
Taiwan
Prior art keywords
peptides
bind
receptor
compounds
Prior art date
Application number
TW093125674A
Other languages
English (en)
Chinese (zh)
Other versions
TW200517103A (en
Inventor
Brian R Macdonald
Jeffery Kenneth Weis
Edward John Yurkow
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI348375(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of TW200517103A publication Critical patent/TW200517103A/zh
Application granted granted Critical
Publication of TWI348375B publication Critical patent/TWI348375B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/524Thrombopoietin, i.e. C-MPL ligand
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/03Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
TW093125674A 2003-08-28 2004-08-27 Peptides and compounds that bind to a receptor TWI348375B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49874003P 2003-08-28 2003-08-28

Publications (2)

Publication Number Publication Date
TW200517103A TW200517103A (en) 2005-06-01
TWI348375B true TWI348375B (en) 2011-09-11

Family

ID=34272720

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093125674A TWI348375B (en) 2003-08-28 2004-08-27 Peptides and compounds that bind to a receptor

Country Status (32)

Country Link
US (1) US7576056B2 (enExample)
EP (1) EP1675606B1 (enExample)
JP (1) JP4848277B2 (enExample)
KR (2) KR101183875B1 (enExample)
CN (2) CN1871022B (enExample)
AR (1) AR045530A1 (enExample)
AU (1) AU2004270656B2 (enExample)
BR (1) BRPI0414008B8 (enExample)
CA (1) CA2537421C (enExample)
CY (1) CY1118965T1 (enExample)
DK (1) DK1675606T3 (enExample)
EA (1) EA009286B1 (enExample)
EC (1) ECSP066396A (enExample)
ES (1) ES2626107T3 (enExample)
HR (1) HRP20170810T1 (enExample)
HU (1) HUE032370T2 (enExample)
IL (1) IL173965A (enExample)
IS (1) IS8300A (enExample)
LT (1) LT1675606T (enExample)
ME (1) ME00313B (enExample)
MX (1) MXPA06002292A (enExample)
NO (1) NO344233B1 (enExample)
NZ (1) NZ545455A (enExample)
PL (1) PL1675606T3 (enExample)
PT (1) PT1675606T (enExample)
RS (2) RS20060141A (enExample)
SG (1) SG131110A1 (enExample)
SI (1) SI1675606T1 (enExample)
TW (1) TWI348375B (enExample)
UA (1) UA82710C2 (enExample)
WO (1) WO2005023834A2 (enExample)
ZA (1) ZA200602495B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
MEP42108A (en) 1998-10-23 2011-02-10 Kiren Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
ES2781475T3 (es) 2002-09-18 2020-09-02 Janssen Pharmaceuticals Inc Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
SG131110A1 (en) 2003-08-28 2007-04-26 Ortho Mcneil Pharm Inc Peptides and compounds that bind to thrombopoietin receptors
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
EP1986677A2 (en) * 2006-01-25 2008-11-05 Amgen Inc. Thrombopoietic compounds
AR059573A1 (es) * 2006-02-14 2008-04-16 Janssen Pharmaceutica Nv Uso de compuestos peptidicos de tpo y composiciones farmaceuticas en el tratamiento de la anemia
DK1984014T3 (da) * 2006-02-14 2014-09-15 Janssen Pharmaceutica Nv Anvendelse af tpo-peptidforbindelser og farmaceutiske sammensætninger ved behandlingen af anæmi
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
ES2729622T3 (es) * 2008-06-03 2019-11-05 Janssen Pharmaceutica Nv Péptido mimético de TPO para prevenir el desorden hematológico asociado al tratamiento contra el cáncer
EP2725053B1 (en) 2011-06-23 2016-02-10 Shimadzu Corporation Branched amphipathic block polymer and molecular aggregate and drug delivery system using same
AU2018306329B8 (en) * 2017-07-26 2025-02-20 Janssen Pharmaceutica Nv Methods of protecting vascular integrity induced by targeted radiation therapy
MX2021008943A (es) 2019-01-25 2021-11-04 Janssen Pharmaceutica Nv Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos.
EP3914286B1 (en) 2019-01-25 2025-05-07 Janssen Pharmaceutica NV Methods of mitigating toxic effects of vesicants and caustic gas
WO2020154637A1 (en) * 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
WO2023056444A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
DK167813B1 (da) 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5571508A (en) 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US5141851A (en) 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
AU680422B2 (en) 1992-06-11 1997-07-31 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
JP3401005B2 (ja) 1992-12-11 2003-04-28 ユニバーシティ オブ フロリダ 有害生物の防除のための材料および方法
WO1995011922A1 (en) 1993-10-29 1995-05-04 Affymax Technologies N.V. In vitro peptide and antibody display libraries
GB2285446B (en) 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
EP0723456A1 (en) 1994-02-14 1996-07-31 The University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
EP0668352A1 (en) 1994-02-14 1995-08-23 Kirin Brewery Company, Ltd. Protein having TPO activity
NZ271230A (en) 1994-02-14 1998-03-25 Zymogenetics Inc Hematopoietic proteins, production and use
GEP20002180B (en) 1994-03-31 2000-07-25 Amgen Inc Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
US5571686A (en) 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
KR100376150B1 (ko) * 1994-11-04 2003-11-01 산텐 세이야꾸 가부시키가이샤 히드록시기를함유하는1,3-디알킬우레아유도체
AU4163196A (en) 1994-11-30 1996-06-19 Zymogenetics Inc. Low molecular weight thrombopoietin
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
JP3763846B2 (ja) 1995-04-26 2006-04-05 協和醗酵工業株式会社 新規ポリペプチド
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6083913A (en) * 1995-06-07 2000-07-04 Glaxo Wellcome Inc. Peptides and compounds that bind to a thrombopoietin receptor
US6251864B1 (en) * 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6060052A (en) 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
WO2001021180A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Corporation Thrombopoietin mimetics
CZ299141B6 (cs) * 2000-12-22 2008-04-30 Ipsen Manufacturing Ireland Limited Zpusob syntézy peptidu LHRH
WO2002078612A2 (en) 2001-04-02 2002-10-10 Euro-Celtique S.A. Thrombopoietin (tpo) synthebody for stimulation of platelet production
ES2781475T3 (es) * 2002-09-18 2020-09-02 Janssen Pharmaceuticals Inc Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
SG131110A1 (en) 2003-08-28 2007-04-26 Ortho Mcneil Pharm Inc Peptides and compounds that bind to thrombopoietin receptors

Also Published As

Publication number Publication date
UA82710C2 (uk) 2008-05-12
ME00313B (me) 2011-05-10
CN1871022B (zh) 2011-07-06
RS56387B1 (sr) 2017-12-29
EA200600477A1 (ru) 2007-02-27
CN1871022A (zh) 2006-11-29
MEP48508A (en) 2011-02-10
JP2007504132A (ja) 2007-03-01
BRPI0414008B8 (pt) 2021-05-25
KR101183875B1 (ko) 2012-09-27
EP1675606A2 (en) 2006-07-05
KR20120078742A (ko) 2012-07-10
TW200517103A (en) 2005-06-01
AU2004270656B2 (en) 2011-03-10
ES2626107T3 (es) 2017-07-24
AR045530A1 (es) 2005-11-02
BRPI0414008A (pt) 2006-10-24
BRPI0414008B1 (pt) 2018-05-15
US20050137133A1 (en) 2005-06-23
EA009286B1 (ru) 2007-12-28
HUE032370T2 (en) 2017-09-28
EP1675606B1 (en) 2017-04-05
EP1675606A4 (en) 2009-09-30
LT1675606T (lt) 2017-11-10
WO2005023834A2 (en) 2005-03-17
CN102241742A (zh) 2011-11-16
HRP20170810T1 (hr) 2017-08-11
CA2537421A1 (en) 2005-03-17
NZ545455A (en) 2009-02-28
CN102241742B (zh) 2014-04-02
PL1675606T3 (pl) 2017-08-31
WO2005023834A3 (en) 2005-05-06
KR20070017942A (ko) 2007-02-13
DK1675606T3 (en) 2017-06-19
CY1118965T1 (el) 2018-01-10
MXPA06002292A (es) 2006-09-04
ECSP066396A (es) 2006-08-30
JP4848277B2 (ja) 2011-12-28
IL173965A (en) 2015-10-29
IS8300A (is) 2006-02-14
NO344233B1 (no) 2019-10-14
SG131110A1 (en) 2007-04-26
AU2004270656A1 (en) 2005-03-17
PT1675606T (pt) 2017-05-22
SI1675606T1 (sl) 2017-07-31
IL173965A0 (en) 2006-07-05
CA2537421C (en) 2011-09-27
ZA200602495B (en) 2007-06-27
HK1096873A1 (en) 2007-06-15
RS20060141A (sr) 2008-08-07
NO20061346L (no) 2006-05-22
US7576056B2 (en) 2009-08-18

Similar Documents

Publication Publication Date Title
TWI348375B (en) Peptides and compounds that bind to a receptor
IL198844A0 (en) Peptides that bind to the erythropoietin receptor
AP2042A (en) Novel peptides that bind to the erythropoietin receptor
GB2409458B (en) Composite materials
GB2401547B (en) Particulate materials
AU2003218456A8 (en) Antibodies that specifically bind to gmad
AU2003234706A8 (en) Antibodies that specifically bind to tl5
EP1708703A4 (en) CHEMOKIN RECEPTOR BINDING COMPOUNDS
AU2003256299A8 (en) Antibodies that specifically bind to reg iv
AU2003240822A8 (en) Antibodies that specifically bind to neurokinin b
GB0216562D0 (en) Particulate materials
GB0208742D0 (en) Particulate materials
IL183123A0 (en) Novel peptides that bind to the erythropoietin receptor
IL173265A0 (en) Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazcpine receptor ligands
AU2003228483A8 (en) Antibodies that specifically bind to tr2
ZA200704988B (en) Particulate materials
GB0329208D0 (en) Particulate materials
GB2393687B (en) Punchless file
GB2449782B (en) Composite materials
GB0304872D0 (en) Improvements relating to particulate material
GB0400484D0 (en) A peptide
GB0314255D0 (en) Back strapping
GB0329964D0 (en) Particulate materials
ZA200509213B (en) Grout bag
GB0205038D0 (en) File conversion

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees